 |
|
Anthracyclines improve survival in HER2-positive breast cancer patients
December 26, 2007Treatment with the class of chemotherapy drugs called anthracyclines improves survival in women with HER2-positive breast cancer who have previously had surgery, but it may not offer any benefit for women with HER2-negative tumors, according to a study published online December 25 in the Journal of the National Cancer Institute.
Randomized clinical trials have demonstrated that treating early breast cancer with anthracycline-based chemotherapy improves disease-free and overall survival rates more than non-anthracycline-based regimens. However, the studies have demonstrated that anthracyclines may slightly increase the risk of heart damage and leukemia. Given these side effects, the greatest benefit of these regimens may be in women with breast tumors that overexpress HER2-a gene that is often amplified in tumors that respond to anthracyclines.
Alessandra Gennari, M.D., Ph.D., of the National Cancer Research Institute in Genoa, Italy, and colleagues compiled data from eight randomized controlled trials that compared anthracyclines and non-anthracyclines, and also reported HER2 status. Almost 30 percent of the patients' tumors overexpressed HER2.
Overall and among patients with HER2-positive tumors, anthracycline-based chemotherapy produced a greater reduction in the risk of relapse or death than non-anthracycline-based regimens. However, among patients with HER2-negative tumors, there was no difference in survival between the chemotherapy regimens.
"The absence-of any effect of anthracyclines observed in patients with HER2-negative disease suggests that this group of patients could be spared unnecessary toxic effects related to the use of this class of agents and raises questions as to the appropriateness of control arms in randomized clinical trials in which anthracycline-based regimens are used in unselected patient populations," the authors write.
In an accompanying editorial, Soonmyung Paik, M.D., of the National Surgical Adjuvant Breast and Bowel Project in Pittsburgh and colleagues point out that HER2 status alone may not be enough to determine who should receive anthracyclines, given the molecular differences among different subtypes of breast cancer.
"Optimization of adjuvant chemotherapy for patients diagnosed with breast cancer will depend on defining the baseline prognosis and chemosensitivity of each subclass of breast cancer beyond those crudely defined by HER2 status alone," the editorialists write.
Journal of the National Cancer Institute
Overall and among patients with HER2-positive tumors, anthracycline-based chemotherapy produced a greater reduction in the risk of relapse or death than non-anthracycline-based regimens. However, among patients with HER2-negative tumors, there was no difference in survival between the chemotherapy regimens.
"The absence-of any effect of anthracyclines observed in patients with HER2-negative disease suggests that this group of patients could be spared unnecessary toxic effects related to the use of this class of agents and raises questions as to the appropriateness of control arms in randomized clinical trials in which anthracycline-based regimens are used in unselected patient populations," the authors write.
In an accompanying editorial, Soonmyung Paik, M.D., of the National Surgical Adjuvant Breast and Bowel Project in Pittsburgh and colleagues point out that HER2 status alone may not be enough to determine who should receive anthracyclines, given the molecular differences among different subtypes of breast cancer.
"Optimization of adjuvant chemotherapy for patients diagnosed with breast cancer will depend on defining the baseline prognosis and chemosensitivity of each subclass of breast cancer beyond those crudely defined by HER2 status alone," the editorialists write.
Journal of the National Cancer Institute
Science News and Science Current Events Tag Cloud
This tag cloud is a visual representation of term frequencies of random science news topics with common terms grouped together and emphasized by their display size.
Coral reef Post-traumatic Stress Diversity Sarcoma Aerosols Genetic Mutation Biodiesel Saturns Rings Extrasolar Planets Nuclear Medicine Bacterium Ecstasy Pollution Yeast Cells Cigarette Smoke Rett Syndrome Chronic inflammation Contact Lenses Anemia Aneurysm Quantum computer Multiple Myeloma Mental Illness ALS Erectile dysfunction
See More: Science News Tags
Anthracyclines Current Events and Anthracyclines News RSSTriple drug combination is promising option to treat metastatic HER2+ breast cancer
Combining two chemotherapy drugs with trastuzumab (Herceptin) to treat women who have metastatic HER2+ breast cancer may offer physicians another choice in their treatment options.
How chemotherapy drugs block blood vessel growth, slow cancer spread
Researchers at the Johns Hopkins University School of Medicine have discovered how a whole class of commonly used chemotherapy drugs can block cancer growth.
HER2 levels may aid in treatment selection for metastatic breast cancer
Findings published in the December 1, 2008, issue of Clinical Cancer Research, a journal of the American Association for Cancer Research, show lapatinib benefits women with HER2-positive breast cancer, while women with HER2-negative breast cancer or those who express EGRF alone derive no incremental benefit.
Herceptin and chemo improves response rates without major adverse effects in HER2 breast cancer
Women with a particularly aggressive form of breast cancer seem to do better if they are treated with a combined anthracycline and taxane chemotherapy regimen before surgery, together with trastuzumab (Herceptin) before and after surgery, according to results from the largest multi-centre trial to investigate this treatment.
Standard chemo works better against metastatic BRCA1/2 breast cancer than against sporadic tumors
The first study to investigate the effects of chemotherapy on metastatic breast cancer in women with the BRCA1 or BRCA2 gene mutation has shown that standard chemotherapy works better in these patients than in women without the BRCA1/2 mutation.
Childhood cancer survivors at increased risk of sarcoma
Survivors of childhood cancers have a ninefold increased risk of developing a secondary sarcoma—a cancer of connective or supportive tissue such as bone, fat, or muscle—compared with the general population.
Study analyzes heart attack mortality risk associated with Hodgkin disease treatments
Doctors have long known that patients treated for Hodgkin disease are at an increased risk for heart attacks.
Genes raise risk of heart disease after treatment for childhood cancer
Gene variations may raise the risk that survivors of childhood cancer will suffer congestive heart failure as a complication of drugs they received during cancer treatment.
Innovative research set to push boundaries of cancer care
Cancer researchers wielding opportunistic bacteria, vaccines, electric pulses, nano buckeyballs, and designer agents that enter the brain are being featured in a "Novel Approaches" press conference at the Molecular Targets and Cancer Therapeutics International Conference.
More children survive cancer but the after-effects present a challenge to doctors
Embargoed: 09.00 hrs CET Wednesday 24 September 2003 Copenhagen, Denmark: The number of children who survive childhood cancer is improving dramatically, but because of the side effects of their treatment the majority continue to need specialist care for many years. This rapid increase in the numbers of survivors means that the medical profession must consider the best and most cost-effective way of caring for them, according to Jill Mann, Professor of Paediatric Oncology at the University of Birmingham, and Emeritus Consultant Paediatric Oncologist at the Birmingham Children's Hospital in the UK. Prof. Mann told delegates at ECCO12 - The European Cancer Conference that a study of 5,016 child
More Anthracyclines Current Events and Anthracyclines News Articles
 |
Anthracycline Chemistry and Biology II: Mode of Action, Clinical Aspects and New Drugs (Topics in Current Chemistry) (No. 2) by Karsten Krohn (Editor) |
 |
Anthracycline Chemistry and Biology I: Biological Occurence and Biosynthesis, Synthesis and Chemistry (Topics in Current Chemistry) (No. 1) by Karsten Krohn (Editor) |
|
Anthracycline Anticancer Agts: (North-Holland Series in Applied Mathematics and Mechanics) by Lown (Author), J. William Lown (Other Contributor) | |
|
Anthracycline Antibiotics by Hassan Saad El Khadem (Editor) | |
|
Anthracycline Antibiotics: New Analogues, Methods of Delivery, and Mechanisms of Action (Acs Symposium Series) by Waldemar Priebe (Editor) Covers the synthesis of promising new analogues. Studies structure-activity relationships of anthracycline antibiotics. Investigates new approaches to improving properties for anthracyclines by using different drug-delivery and tumor-targeting systems. Covers the mechanisms of action of anthracyclines, their interactions with cellular targets, and related biological and clinical aspects. | |
 |
Chemotherapy: Arsphenamine, History of cancer chemotherapy, Acute myeloid leukemia, Alkylating antineoplastic agent, Anthracycline, Monoclonal antibodies, Paclitaxel, Docetaxel, Doxorubicin by John McBrewster (Editor), Frederic P. Miller (Editor), Agnes F. Vandome (Editor) Chemotherapy - Arsphenamine, History of cancer chemotherapy, Acute myeloid leukemia, Alkylating antineoplastic agent, Anthracycline, Monoclonal antibodies, Paclitaxel, Docetaxel, Doxorubicin, Bleomycin, Hematopoietic stem cell transplantation, Port (medical), Granisetron, Ondansetron, Post-chemotherapy cognitive impairment, Mucositis, Vinorelbine |
|
Discovery and Development of Anthracycline Antitumor Antibiotics. by CARMEN MARAN (Author) | |
|
Anthracycline Antibiotics: New Analogues, Methods of Delivery, and Mechanisms of by Editor-Waldemar Priebe (Author) | |
![The relationship between fatigue and quality of life and inflammation during anthracycline-based chemotherapy in breast cancer [An article from: Biological Psychology]](http://ecx.images-amazon.com/images/I/51H6KB16YQL._SL160_.jpg) |
The relationship between fatigue and quality of life and inflammation during anthracycline-based chemotherapy in breast cancer [An article from: Biological Psychology] by P.J. Mills (Author), B. Parker (Author), J.E. Dimsdale (Author), G.R. Sadler (Author) This digital document is a journal article from Biological Psychology, published by Elsevier in 2005. The article is delivered in HTML format and is available in your Amazon.com Media Library immediately after purchase. You can view it with any web browser. Description: Chemotherapy for breast cancer leads to increased fatigue, poor mood, and reduced quality of life. Few studies have examined possible changes in inflammation during chemotherapy as potential contributors to this phenomenon. This study examined the relationship among circulating levels of soluble intercellular adhesion molecule-1 (sICAM-1), vascular endothelial growth factor (VEGF) and interleukin-6 (IL-6) and fatigue, depressed mood, and quality of life before and during anthracycline-based chemotherapy.... |
|
Cardiovascular Toxicology. Special Issue, Anthracycline cardiotocixity: Molecular Mechanisms and Clinical Correlates by Y. J. Kang (Author) |
| © 2009 BrightSurf.com |